4SC AG Company Profile - Aug 16, 2011

Document Sample
4SC AG Company Profile - Aug 16, 2011 Powered By Docstoc
					Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   4SC Ag
                                                                                       440 Wheelers Farms Road
                                                                                       Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Euro

                                 Wright Quality Rating:DANN                                 Key Data

   4SC Ag. 4SC AG is a Germany-based research-oriented drug discovery and                   Ticker:
   development Company. Its research activities center on cancer and autoimmune             VSC
   indications. The Company develops drug candidates until proof-of-concept in order
   to generate value creating partnerships with the pharmaceutical industry in return       2010 Sales:
   for advance and payments as well as royalties. It collaborates with AiCuris in the
                                                                                            989,000
   field of antiviral and antibacterial drug discovery, with ProQinase to identify a new
   generation of protein kinase inhibitors in order to develop anticancer drugs, with and
   ViroLogik in the field of developing, manufacturing and market the compound for viral    Major Industry:
   diseases.                                                                                Drugs, Cosmetics & Health
                                                                                            Care
                       Stock Chart                                   Officers
                                                                    Chairman
                                                               Dr. Joerg Neermann           Sub Industry:
                                                                                            Ethical Drug Manufacturers
                                                          Chairman & Chief Executive
                                                                Dr. Ulrich Dauer     Country:
                                                                                     Germany

                                                                                            Currency:
                                                                                            Euro

                                                                                            Fiscal Year Ends:
                                                                                            December

                                                                                            Employees
                                                                                            94

                                                                                            Exchanges:
                                                                                            FRA
             Stock Price (8/12/2011): 1.58
               Recent stock performance                                                     Share Type:
                  1 Week        5.3%
                                                                                            Stammaktie
                  4 Weeks     -15.5%
                  13 Weeks    -57.3%
                  52 Weeks    -41.5%                                                        Market Capitalization:
                                                                                            66,309,920
                       Earnings / Dividends (as of 6/30/2011)
                       
				
DOCUMENT INFO
Description: 4SC Ag. 4SC AG is a Germany-based research-oriented drug discovery and development Company. Its research activities center on cancer and autoimmune indications. The Company develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and payments as well as royalties. It collaborates with AiCuris in the field of antiviral and antibacterial drug discovery, with ProQinase to identify a new generation of protein kinase inhibitors in order to develop anticancer drugs, with and ViroLogik in the field of developing, manufacturing and market the compound for viral diseases.
BUY THIS DOCUMENT NOW PRICE: $24.95 100% MONEY BACK GUARANTEED
PARTNER Wright Investors' Service
Wright Investors' Service is an internationally recognized investment management and financial advisory firm headquartered in Milford, Connecticut. For more than 40 years, Wright has used well-defined and sophisticated investment strategies to help institutions, plan sponsors, bank trust departments, trust companies and individual investors achieve their financial objectives through a sensible approach to managing assets that balances risk and return.